Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,828 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection.
Tsuge M, Hiraga N, Uchida T, Kan H, Miyaki E, Masaki K, Ono A, Nakahara T, Abe-Chayama H, Zhang Y, Naswa MG, Kawaoka T, Miki D, Imamura M, Kawakami Y, Aikata H, Ochi H, Hayes CN, Chayama K. Tsuge M, et al. Among authors: kawakami y. J Gastroenterol. 2016 Nov;51(11):1073-1080. doi: 10.1007/s00535-016-1189-x. Epub 2016 Mar 4. J Gastroenterol. 2016. PMID: 26943168 Clinical Trial.
Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.
Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Jeong SC, et al. Among authors: kawakami y. World J Gastroenterol. 2007 Oct 28;13(40):5343-50. doi: 10.3748/wjg.v13.i40.5343. World J Gastroenterol. 2007. PMID: 17879404 Free PMC article.
Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial.
Kawaoka T, Kawakami Y, Tsuji K, Ito H, Kitamoto M, Aimitsu S, Kawakami H, Jeong SC, Imamura M, Aikata H, Takahashi S, Chayama K. Kawaoka T, et al. Among authors: kawakami y, kawakami h. J Gastroenterol Hepatol. 2009 Mar;24(3):366-71. doi: 10.1111/j.1440-1746.2008.05650.x. Epub 2008 Nov 20. J Gastroenterol Hepatol. 2009. PMID: 19032459 Clinical Trial.
Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.
Mitsui F, Tsuge M, Kimura T, Kitamura S, Abe H, Saneto H, Kawaoka T, Miki D, Hatakeyama T, Hiraga N, Imamura M, Kawakami Y, Aikata H, Takahashi S, Hayes CN, Igarashi H, Morimoto K, Shimizu M, Chayama K. Mitsui F, et al. Among authors: kawakami y. Antimicrob Agents Chemother. 2010 Aug;54(8):3205-11. doi: 10.1128/AAC.01372-09. Epub 2010 May 24. Antimicrob Agents Chemother. 2010. PMID: 20498322 Free PMC article. Clinical Trial.
Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy.
Nagaoki Y, Aikata H, Miyaki D, Murakami E, Hashimoto Y, Katamura Y, Azakami T, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Chayama K. Nagaoki Y, et al. Among authors: kawakami y. J Gastroenterol. 2011 Jun;46(6):799-808. doi: 10.1007/s00535-011-0384-z. Epub 2011 Mar 4. J Gastroenterol. 2011. PMID: 21373851
Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H, Chayama K. Kawaoka T, et al. Among authors: kawakami y. J Gastroenterol Hepatol. 2012 Sep;27(9):1467-72. doi: 10.1111/j.1440-1746.2012.07129.x. J Gastroenterol Hepatol. 2012. PMID: 22432893
Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis.
Nagaoki Y, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Takahashi S, Ochi H, Chayama K. Nagaoki Y, et al. Among authors: kawakami y. J Gastroenterol. 2013 Jul;48(7):847-55. doi: 10.1007/s00535-012-0679-8. Epub 2012 Oct 5. J Gastroenterol. 2013. PMID: 23053422
2,828 results